Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.

Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.

The popular DOAC was linked to more bleeding events than warfarin, but fewer reports of intracardiac thrombi and other adverse outcomes. Researchers presented their findings at the AHA's Scientific Sessions 2024 conference in Chicago.

The popular diabetes drug, which can also benefit patients with heart failure and sleep apnea, resulted in an average weight loss of 23%. Once treatment stopped, the effects started to fade rather quickly. 

Sanjit S. Jolly, MD, MSc, reviewed his team's late-breaking data on treating heart attack patients with colchicine. "I think inflammation is an important area, but I don't think colchicine is the magic bullet," he said.

The three-day conference begins Saturday, Nov. 16, in Chicago. Topics will include AI, heart failure, patient management and much more. 

Treating AMI patients with colchicine is not associated with better cardiovascular outcomes, according to new data presented at TCT. The drug did help with inflammation, but that was the only benefit researchers could identify.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country.